The patent for podophyllotoxin, a new anti-tumor drug of Jianfeng pharmaceutical, was approved

Zhejiang Jianfeng Pharmaceutical Co., Ltd., the holding subsidiary of Jianfeng group, has issued a patent certificate for the patent "a preparation method of deoxypodophyllotoxin" It is understood that the drug was jointly developed by Pinnacle pharmaceutical and Institute of pharmaceutical and chemical engineering of China Pharmaceutical University It has applied for a number of domestic and international patents and is a new anti-tumor drug Deoxypodophyllotoxin (DPT) is a compound extracted and purified from lignin plants The international clinical application shows that DPT has significant inhibitory effect on six kinds of human tumor cells and one kind of animal tumor cells The raw material used in the invention has a wide range of sources and low price, and is suitable for industrial production The data shows that since 2007, China's anti-tumor drug market has maintained a growth rate of more than 22% In 2012, the market scale is close to 80 billion yuan, and the market growth rate is about 26% The market development momentum is good At present, taxol and docetaxel are the first and second anti-tumor drugs in China, with annual sales over 3 billion yuan It is reported that DPT, paclitaxel and docetaxel belong to the same class of drugs, with similar mechanism of action, and compared with paclitaxel, DPT has no inferior antitumor activity, especially for drug-resistant tumor strains, with low toxicity (especially DPT's cardiotoxicity, liver toxicity and bone marrow toxicity are low), etc Therefore, the industry expects that DPT application prospects are likely to exceed paclitaxel Once the DPT product is listed, there is a huge market space at home and abroad, and the drug is expected to become a heavyweight product with independent intellectual property rights in China On April 16, 2012, Jianfeng pharmaceutical and the Institute of pharmaceutical and chemical engineering of China Pharmaceutical University officially signed a cooperative development agreement for a class I anti-cancer drug, podophyllotoxin (DPT), with a contract amount of 30 million yuan.